Ramy Mahmoud - OptiNose President COO
OPTN Stock | USD 1.46 0.02 1.35% |
President
Dr. Ramy A. Mahmoud, M.D. serves as President, Chief Operating Officer the Company. Prior to joining us, Dr. Mahmoud spent 14 years at Johnson Johnson, where he served as Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his tenure at Johnson Johnson, he also held senior roles in the pharmaceutical sector. Dr. Mahmoud served for 10 years on active duty in the U.S. Army and an additional 10 years in the Army Reserves, achieving the rank of Lieutenant Colonel. During his military service, Dr. Mahmoud held various patient care, research, and academic positions, culminating in his position as the head of the Department of Epidemiology at the Walter Reed Army Institute of Research. He has published more than 50 peerreviewed papers and textbook chapters, and has served as a scientific reviewer for a number of journals and textbooks since 2010.
Age | 53 |
Tenure | 14 years |
Address | 1020 Stony Hill Road, Yardley, PA, United States, 19067 |
Phone | 267 364 3500 |
Web | https://www.optinose.com |
Ramy Mahmoud Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ramy Mahmoud against OptiNose stock is an integral part of due diligence when investing in OptiNose. Ramy Mahmoud insider activity provides valuable insight into whether OptiNose is net buyers or sellers over its current business cycle. Note, OptiNose insiders must abide by specific rules, including filing SEC forms every time they buy or sell OptiNose'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ramy Mahmoud over three weeks ago Acquisition by Ramy Mahmoud of 7988 shares of OptiNose at 1.815 subject to Rule 16b-3 |
OptiNose Management Efficiency
The company has return on total asset (ROA) of (0.1129) % which means that it has lost $0.1129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.505) %, meaning that it created substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities. At this time, OptiNose's Return On Capital Employed is very stable compared to the past year. As of the 29th of March 2024, Return On Equity is likely to grow to 0.43, while Return On Assets are likely to drop (0.35). At this time, OptiNose's Total Assets are very stable compared to the past year. As of the 29th of March 2024, Other Current Assets is likely to grow to about 4.2 M, though Net Tangible Assets are likely to grow to (61.9 M).Similar Executives
Found 2 records | PRESIDENT Age | ||
Bill Aurora | Neurocrine Biosciences | N/A | |
DavidAlexandre Gros | Neurocrine Biosciences | 43 |
Management Performance
Return On Equity | -10.5 | ||||
Return On Asset | -0.11 |
OptiNose Leadership Team
Elected by the shareholders, the OptiNose's board of directors comprises two types of representatives: OptiNose inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OptiNose. The board's role is to monitor OptiNose's management team and ensure that shareholders' interests are well served. OptiNose's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OptiNose's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sandra Helton, Independent Director | ||
Anthony Krick, Vice Officer | ||
Ramy Mahmoud, President COO | ||
John Messina, Sr Affairs | ||
Jonathan Neely, Vice President - Investor Relations and Business Operations | ||
Joshua Tamaroff, Independent Director | ||
Joseph Scodari, Independent Chairman of the Board | ||
Keith Goldan, CFO | ||
Sriram Venkataraman, Independent Director | ||
Wilhelmus Groenhuysen, Independent Director | ||
Peter Miller, CEO, Director | ||
Larry Pickering, Independent Vice Chairman of the Board | ||
Michele MBA, VP CFO | ||
Thomas Gibbs, Chief Commercial Officer | ||
Robert ONeil, Independent Director | ||
Paul Spence, Chief Officer | ||
Karen Brophy, Chief Resources | ||
William Doyle, Independent Director | ||
Michael Esq, Chief Secretary | ||
Victor Clavelli, Chief Officer | ||
Per MD, CoFounder AS | ||
Michael Marino, Chief Legal Officer and Corporate Secretary | ||
MPH MD, CEO Director |
OptiNose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OptiNose a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -10.5 | ||||
Return On Asset | -0.11 | ||||
Profit Margin | (0.50) % | ||||
Operating Margin | (0.13) % | ||||
Current Valuation | 223.66 M | ||||
Shares Outstanding | 112.65 M | ||||
Shares Owned By Insiders | 8.90 % | ||||
Shares Owned By Institutions | 77.61 % | ||||
Number Of Shares Shorted | 3.2 M | ||||
Price To Earning | (3.41) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for OptiNose Stock analysis
When running OptiNose's price analysis, check to measure OptiNose's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OptiNose is operating at the current time. Most of OptiNose's value examination focuses on studying past and present price action to predict the probability of OptiNose's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OptiNose's price. Additionally, you may evaluate how the addition of OptiNose to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is OptiNose's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Revenue Per Share 0.633 | Quarterly Revenue Growth (0.05) | Return On Assets (0.11) | Return On Equity (10.51) |
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.